Description of Invention:
This invention details methods of use and composition of matter for preparing biliverdin. Biliverdin has been shown to have cytoprotective properties similar to bilirubin and can be used in the treatment of cardiovascular diseases, cancer, organ transplantation and other indications where inflammation occurs.
Incubating bilirubin with a bilirubin oxidase from various biological sources produces biliverdin. Like bilirubin, biliverdin has been shown to have these cytoprotective properties but is more soluble, reduced toxicity and as such, reduced side effects. Thus biliverdin is a safer alternative to bilirubin for therapeutic treatment of cardiovascular disease, cancers, inflammation and Alzheimer's in both human and non-human mammals.
The current technology involves methods of use and compositions of matter for the production and collection of biliverdin from microorganisms, including the yeast Candida albicans. Further claims include methods to enhance biliverdin production in microorganisms and use of biliverdin in the production of pharmaceuticals.
Inventors:
Michael L. Pendrak (NCI) David D. Roberts (NCI)
Patent Status:
DHHS Reference No. E-040-2004/0 --
U.S. Provisional Application No. 60/554,369 filed 19 Mar 2004
U.S. Patent Application No. 11/078,552 filed 14 Mar 2005
Portfolios: Internal Medicine Infectious Diseases Central Nervous System Cancer
Cancer -Therapeutics-Biological Response Modifiers-Other Central Nervous System -Therapeutics-Neurological Therapeutics-Alzheimer Central Nervous System -Therapeutics-Neurological Therapeutics-Stroke Central Nervous System -Therapeutics-Neurological Therapeutics-Other Cancer -Therapeutics Central Nervous System -Therapeutics Infectious Diseases -Therapeutics Internal Medicine-Therapeutics
For Additional Information Please Contact: Robert M. Joynes J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)594-6565
Email: joynesr@mail.nih.gov
Fax: (301) 402-0220